- Home
- Publications
- Publication Search
- Publication Details
Title
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Authors
Keywords
-
Journal
Cells
Volume 11, Issue 16, Pages 2508
Publisher
MDPI AG
Online
2022-08-15
DOI
10.3390/cells11162508
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure–Activity Relationship Studies
- (2022) Xufen Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Landscape of PDK1 in Breast Cancer
- (2022) Na Wang et al. Cancers
- The role of network‐forming collagens in cancer progression
- (2022) Jin Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy
- (2022) Yangfu Jiang et al. Journal of Hematology & Oncology
- mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
- (2022) David Casadevall et al. MOLECULAR CANCER RESEARCH
- In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines
- (2022) Sandeep Kumar et al. Breast Disease
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
- (2022) N. Lynn Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
- (2022) Sacha J Howell et al. LANCET ONCOLOGY
- BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
- (2021) Yu Li et al. Scientific Reports
- Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
- (2021) Niamh M. Keegan et al. Cancers
- Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
- (2021) Bora Lim et al. CLINICAL CANCER RESEARCH
- Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
- (2021) Chi Yan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery
- (2021) Amit Kumar Halder et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
- (2021) Hope S Rugo et al. LANCET ONCOLOGY
- Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
- (2021) Chao Dong et al. Frontiers in Pharmacology
- Targeting Akt in cancer for precision therapy
- (2021) Hui Hua et al. Journal of Hematology & Oncology
- The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings
- (2021) Ryann E. Shor et al. Molecular Oncology
- PI3K inhibitors are finally coming of age
- (2021) Bart Vanhaesebroeck et al. NATURE REVIEWS DRUG DISCOVERY
- In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
- (2021) Meiou Dai et al. Nature Communications
- RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (Inavolisib) efficacy
- (2021) Kyung W Song et al. Cancer Discovery
- TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients
- (2021) Cecile Vicier et al. EUROPEAN JOURNAL OF CANCER
- The Role of Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 in the Pathogenesis of Human Cancer
- (2021) Chien-An Chu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
- (2020) F. Coussy et al. Journal of Hematology & Oncology
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
- (2020) Robert H Jones et al. LANCET ONCOLOGY
- Role of Akt Activation in PARP Inhibitor Resistance in Cancer
- (2020) Ferenc Gallyas Jr et al. Cancers
- Overcoming Endocrine Resistance in Breast Cancer
- (2020) Ariella B. Hanker et al. CANCER CELL
- Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
- (2020) Le-Sang Shen et al. CHINESE MEDICAL JOURNAL
- Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
- (2020) Lillian M Smyth et al. CLINICAL CANCER RESEARCH
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
- (2020) A. Jo Chien et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
- (2020) Abderrahim El Guerrab et al. Scientific Reports
- Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways
- (2020) Qiang Zhang et al. BIOMEDICINE & PHARMACOTHERAPY
- Combined targeting of G protein‐coupled receptor and EGF receptor signaling overcomes resistance to PI 3K pathway inhibitors in PTEN ‐null triple negative breast cancer
- (2020) Davide Zecchin et al. EMBO Molecular Medicine
- Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy
- (2020) Hui Hua et al. Journal of Hematology & Oncology
- Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
- (2020) Timothy A. Yap et al. Cancer Discovery
- Inhibition of class I PI3K enhances chaperone-mediated autophagy
- (2020) S. Joseph Endicott et al. JOURNAL OF CELL BIOLOGY
- Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
- (2020) Yumi Fujimoto et al. Scientific Reports
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
- (2020) Kevin Kalinsky et al. JAMA Oncology
- Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
- (2020) S. Dent et al. ANNALS OF ONCOLOGY
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
- (2020) F. André et al. ANNALS OF ONCOLOGY
- PIK3CA in cancer: The past 30 years
- (2019) Rand Arafeh et al. SEMINARS IN CANCER BIOLOGY
- Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2
- (2019) Aleix Prat et al. ONCOLOGIST
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
- (2019) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
- (2019) N C Turner et al. ANNALS OF ONCOLOGY
- Targeting the PI3-kinase pathway in triple-negative breast cancer
- (2019) J Pascual et al. ANNALS OF ONCOLOGY
- PI3K isoforms in cell signalling and vesicle trafficking
- (2019) Benoit Bilanges et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Class II PI3K Functions in Cell Biology and Disease
- (2019) Federico Gulluni et al. TRENDS IN CELL BIOLOGY
- FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
- (2019) M Oliveira et al. ANNALS OF ONCOLOGY
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- Targeting mTOR for cancer therapy
- (2019) Hui Hua et al. Journal of Hematology & Oncology
- Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
- (2019) Franziska Maria Ippen et al. NEURO-ONCOLOGY
- PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges
- (2019) Mohammad A. Khan et al. DRUG DISCOVERY TODAY
- Breast cancer
- (2019) Nadia Harbeck et al. Nature Reviews Disease Primers
- Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Peter Schmid et al. JAMA Oncology
- Efficacy of PI3K inhibitors in advanced breast cancer
- (2019) B Verret et al. ANNALS OF ONCOLOGY
- Distinct functions of AKT isoforms in breast cancer: a comprehensive review
- (2019) Nico Hinz et al. Cell Communication and Signaling
- PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
- (2019) Carlotta Costa et al. Cancer Discovery
- Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer
- (2019) Dongbo Li et al. CANCER SCIENCE
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
- (2018) Sarika Jain et al. BREAST CANCER RESEARCH AND TREATMENT
- Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
- (2018) Karineh Petrossian et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
- (2018) Noah Kornblum et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
- (2018) Ramesh Butti et al. Molecular Cancer
- Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases
- (2018) Neal Shah et al. PHARMACOLOGICAL RESEARCH
- Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
- (2018) Li Chen et al. Nature Communications
- The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment
- (2018) Hanjiao Qin et al. PeerJ
- Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
- (2018) Guy Jerusalem et al. JAMA Oncology
- PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
- (2017) Mathilde Guerin et al. EUROPEAN JOURNAL OF CANCER
- Pathway-based classification of breast cancer subtypes
- (2017) Alex Graudenzi Frontiers in Bioscience-Landmark
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Multifunctional Nanoparticles Loading with Docetaxel and GDC0941 for Reversing Multidrug Resistance Mediated by PI3K/Akt Signal Pathway
- (2017) Yiyue Wang et al. MOLECULAR PHARMACEUTICS
- VPS34 stimulation of p62 phosphorylation for cancer progression
- (2017) X Jiang et al. ONCOGENE
- PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
- (2017) Nandini Dey et al. PHARMACOLOGY & THERAPEUTICS
- MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
- (2017) Ru-Fang Xiang et al. Cell Death & Disease
- Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer
- (2017) Reva K. Basho et al. JAMA Oncology
- Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
- (2016) P. Vuylsteke et al. ANNALS OF ONCOLOGY
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110
- (2016) Y. Nakanishi et al. CANCER RESEARCH
- Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
- (2016) Fabrice André et al. JOURNAL OF CLINICAL ONCOLOGY
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications
- (2016) Benjamin Fourneaux et al. Oncotarget
- Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
- (2015) Carlos Acevedo-Gadea et al. BREAST CANCER RESEARCH AND TREATMENT
- mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR
- (2015) Yancun Yin et al. CELL RESEARCH
- PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
- (2015) Ana Bosch et al. Science Translational Medicine
- Correlation between Activation of PI3K/AKT/mTOR Pathway and Prognosis of Breast Cancer in Chinese Women
- (2015) Ling Deng et al. PLoS One
- Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
- (2014) K.D. Tang et al. CURRENT MEDICINAL CHEMISTRY
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate
- (2013) York Posor et al. NATURE
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
- (2012) Sylvia S. Gayle et al. Anti-Cancer Agents in Medicinal Chemistry
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
- (2012) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
- (2012) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
- (2011) Shujie Yang et al. PLoS One
- A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic
- (2010) Sigrid B. Thoresen et al. EXPERIMENTAL CELL RESEARCH
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse somatic mutation patterns and pathway alterations in human cancers
- (2010) Zhengyan Kan et al. NATURE
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
- (2010) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2009) Matthew J. Ellis et al. BREAST CANCER RESEARCH AND TREATMENT
- PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer
- (2009) R. J. Crowder et al. CANCER RESEARCH
- PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
- (2009) K. Kalinsky et al. CLINICAL CANCER RESEARCH
- PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
- (2009) Elena López-Knowles et al. INTERNATIONAL JOURNAL OF CANCER
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now